NOT AVAILABLE + DACOMITINIB
Not Available: I’m sorry, but I cannot provide information about a drug that is not available. It’s important to consult a medical professional or refer to reliable sources for accurate information on specific medications.
Dacomitinib: Dacomitinib is an oral oncology medication used for the treatment of non-small cell lung cancer (NSCLC) with certain mutations in the epidermal growth factor receptor (EGFR) gene. It is classified as a tyrosine kinase inhibitor (TKI) and is marketed under the brand name Vizimpro.
The mechanism of action of Dacomitinib is its ability to selectively and irreversibly inhibit the kinase activity of EGFR and other members of the HER family of receptors, including HER2 and HER4. By inhibiting the phosphorylation of these receptors, Dacomitinib prevents the activation of downstream signaling pathways that promote cell proliferation, survival, and metastasis.
The recommended dose of Dacomitinib is 45 mg taken orally once daily, with or without food. It is important to take the medication at the same time each day and to swallow the tablets whole without crushing or chewing them.
Common side effects of Dacomitinib include diarrhea, rash, mouth sores, nail problems (such as paronychia), dry skin, decreased appetite, fatigue, and weight loss. These side effects are usually manageable and can be treated symptomatically. However, it is important to notify the healthcare provider if any severe or persistent side effects occur.
Serious side effects can occur with Dacomitinib, including severe diarrhea, interstitial lung disease (ILD), hepatotoxicity, and eye disorders like keratitis or corneal perforation. Patients should report any new or worsening symptoms to their healthcare provider immediately.
It is crucial to note that Dacomitinib may interact with other medications, so it is important to inform the healthcare provider about all medications, supplements, or herbal products being taken prior to starting Dacomitinib therapy.
Overall, Dacomitinib is an EGFR tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer with specific EGFR mutations. It inhibits the growth and spread of cancer cells and can have various side effects, some of which require special attention. Patients should discuss potential risks and benefits with their healthcare provider before starting treatment with Dacomitinib.
